LMR Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.72M Sell
8,100
-172,200
-96% -$176M 0.04% 429
2026
Q1
$166M Buy
+180,300
New +$183M 0.37% 24
2025
Q3
Sell
-96,700
Closed -$75.4M 1566
2025
Q2
$75.4M Hold
96,700
0.54% 31
2025
Q1
$79.9M Buy
+96,700
New +$80.5M 0.75% 16
2024
Q1
Sell
-47,000
Closed -$27.4M 1245
2023
Q4
$27.4M Buy
47,000
+22,100
+89% +$12.9M 0.31% 71
2023
Q3
$13.4M Sell
24,900
-155,900
-86% -$80.3M 0.15% 154
2023
Q2
$84.8M Buy
+180,800
New +$75.8M 0.94% 12

Other funds holding LLY

LMR Partners's LLY Position: Q2 2026 in Review

LMR Partners reduced its Eli Lilly (LLY) stake by 96% in Q2 2026, selling an estimated $92.1M and leaving 3,390 shares worth $4.07M. The position accounts for 0.02% of the portfolio, ranked #712.

LMR Partners first reported a position in LLY in Q2 2015 and has held it in 24 quarters since. The position peaked at $86M in Q1 2026. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • LMR Partners held 3,390 shares of Eli Lilly worth $4.07M as of Q2 2026.
  • LMR Partners sold 90,149 Eli Lilly shares in Q2 2026, an estimated $92.1M.
  • Eli Lilly made up 0.02% of LMR Partners's portfolio in Q2 2026, its #712 holding.
  • LMR Partners first reported a position in Eli Lilly in Q2 2015 and has held it in 24 quarters since.
  • LMR Partners's Eli Lilly position peaked at $86M in Q1 2026.
  • 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.